Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Finished Goods (2016 - 2020)

United Therapeutics' Finished Goods history spans 11 years, with the latest figure at $43.8 million for Q1 2020.

  • On a quarterly basis, Finished Goods fell 7.98% to $43.8 million in Q1 2020 year-over-year; TTM through Mar 2020 was $43.8 million, a 7.98% decrease, with the full-year FY2019 number at $43.2 million, down 11.29% from a year prior.
  • Finished Goods hit $43.8 million in Q1 2020 for United Therapeutics, up from $43.2 million in the prior quarter.
  • Over the last five years, Finished Goods for UTHR hit a ceiling of $62.2 million in Q3 2017 and a floor of $37.3 million in Q2 2016.
  • Historically, Finished Goods has averaged $48.9 million across 5 years, with a median of $48.7 million in 2018.
  • Biggest five-year swings in Finished Goods: soared 65.15% in 2017 and later decreased 20.58% in 2018.
  • Tracing UTHR's Finished Goods over 5 years: stood at $49.7 million in 2016, then increased by 12.47% to $55.9 million in 2017, then decreased by 12.88% to $48.7 million in 2018, then decreased by 11.29% to $43.2 million in 2019, then grew by 1.39% to $43.8 million in 2020.
  • Business Quant data shows Finished Goods for UTHR at $43.8 million in Q1 2020, $43.2 million in Q4 2019, and $45.0 million in Q3 2019.